Anticonvulsant agent 7
Anticonvulsant agent 7 is an orally active, broad-spectrum anticonvulsant that does not rely on direct blockade of Na+/Ca2+ channels. Anticonvulsant agent 7 can be used in seizure research[1].
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C17H23N3O3
- Masse moléculaire:317.38
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
Description
In Vivo
Anticonvulsant agent 7 (30-300 mg/kg; i.p.; single administration) protects mice against scPTZ (absence/myoclonic)-induced seizures[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED50 of 11.1 mg/kg against psychomotor seizures induced by 6 Hz (32 mA), with a protective index > 9.0[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED50 of 40.9 mg/kg against drug-resistant seizures induced by 6 Hz (44 mA), with a protective index > 2.5[1].
Anticonvulsant agent 7 (30 mg/kg; p.o.; single administration) protects up to 100% of rats against MES-induced seizures, with the peak protective effect achieved at 0.5 h post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CF1 mice (male); CD-1 mice (male, 20-26 g)[1]
-
Dosage:30 mg/kg; 100 mg/kg; 300 mg/kg (preliminary screening); 26.3 mg/kg (ED50 determination)
-
Administration:i.p.; single dose
-
Result:Protected 100% of mice at 0.5 h and 4 h post-administration.
Achieved a median effective dose (ED50) of 26.3 mg/kg (i.p.).
Demonstrated a protective index (PI) of >3.8 relative to neurotoxicity (TD50 >100 mg/kg).
-
Animal Model:CF1 mice (male); CD-1 mice (male, 20-26 g)[1]
-
Dosage:30 mg/kg; 100 mg/kg; 300 mg/kg
-
Administration:i.p.; single dose
-
Result:Protected 100% of mice at 0.5 h and 4 h post-administration at 100 mg/kg (i.p.).
-
Animal Model:Sprague-Dawley rats (male, albino)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; single dose
-
Result:Protected 50% of rats at 0.25 h post-administration.
Protected 100% of rats at 0.5 h post-administration.
Protected 75% of rats at 1 h post-administration.
Protected 50% of rats at 2 h post-administration.
Protected 50% of rats at 3 h post-administration.
Chemical Information
-
Masse moléculaire 317.38
-
Formule C17H23N3O3
-
SMILES
O=C1N(CN2CCOCC2)C(C(C3=CC=CC=C3)(C(C)C)N1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticonvulsant agent 7 Related Classifications
HY-170801 Related Classifications
Powered by Bioz
Keywords
- Anticonvulsant agent 7
- Anticonvulsant agent7
- Anticonvulsant agent-7
- Calcium Channel
- Sodium Channel
- mice
- MES-induced seizures
- pharmacoresistant seizures
- rats
- scPTZ-induced seizures
- oxaliplatin-induced tactile allodynia
- L-type Ca2+ channels
- L-type Na+ channels
- psychomotor seizures
- oxaliplatin-induced neuropathic pain
- Inhibitor
- inhibitor
- inhibit